Chemicals · SUDEEPPH
Chemicals - Speciality
from 959 today
Sudeep Pharma reported consolidated revenue of INR1.6bn in Q1FY27, up 27% YoY but down 13% QoQ. We maintain our 'REDUCE' rating with a revised target price of INR855, valuing the company at 45x FY28 EPS.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
